Handelsbanken Fonder AB lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 36.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,306 shares of the medical research company’s stock after buying an additional 5,200 shares during the quarter. Handelsbanken Fonder AB’s holdings in Charles River Laboratories International were worth $4,378,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also recently added to or reduced their stakes in CRL. Czech National Bank increased its position in shares of Charles River Laboratories International by 2.3% in the 2nd quarter. Czech National Bank now owns 13,710 shares of the medical research company’s stock worth $3,109,000 after purchasing an additional 307 shares during the last quarter. PensionDanmark Pensionsforsikringsaktieselskab boosted its holdings in shares of Charles River Laboratories International by 5.4% in the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 14,500 shares of the medical research company’s stock valued at $3,288,000 after buying an additional 740 shares during the period. Assenagon Asset Management S.A. boosted its holdings in shares of Charles River Laboratories International by 178.3% in the 2nd quarter. Assenagon Asset Management S.A. now owns 61,821 shares of the medical research company’s stock valued at $14,020,000 after buying an additional 39,610 shares during the period. Trust Asset Management LLC bought a new stake in shares of Charles River Laboratories International during the 2nd quarter valued at about $129,000. Finally, GAMMA Investing LLC raised its stake in Charles River Laboratories International by 8.9% during the second quarter. GAMMA Investing LLC now owns 3,776 shares of the medical research company’s stock worth $856,000 after acquiring an additional 308 shares during the period. 98.91% of the stock is owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other Charles River Laboratories International news, EVP Shannon M. Parisotto sold 3,714 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $279.66, for a total transaction of $1,038,657.24. Following the transaction, the executive vice president directly owned 4,807 shares in the company, valued at $1,344,325.62. This trade represents a 43.59% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Birgit Girshick sold 6,500 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $279.90, for a total value of $1,819,350.00. Following the completion of the sale, the chief executive officer directly owned 36,013 shares of the company’s stock, valued at $10,080,038.70. This represents a 15.29% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 129,817 shares of company stock worth $31,774,935 in the last 90 days. 1.30% of the stock is owned by corporate insiders.
Charles River Laboratories International Price Performance
Charles River Laboratories International (NYSE:CRL – Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, beating analysts’ consensus estimates of $2.77 by $0.25. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.Charles River Laboratories International’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, analysts forecast that Charles River Laboratories International, Inc. will post 11.35 earnings per share for the current year.
Analyst Upgrades and Downgrades
A number of equities analysts have commented on the company. Evercore restated an “outperform” rating on shares of Charles River Laboratories International in a research note on Wednesday, August 5th. Sanford C. Bernstein set a $250.00 price target on Charles River Laboratories International in a research report on Wednesday, July 1st. Morgan Stanley raised their price target on Charles River Laboratories International from $260.00 to $300.00 and gave the stock an “overweight” rating in a report on Friday, August 7th. TD Cowen boosted their price objective on Charles River Laboratories International from $235.00 to $300.00 and gave the company a “buy” rating in a research report on Monday. Finally, JPMorgan Chase & Co. raised Charles River Laboratories International from a “neutral” rating to an “overweight” rating and increased their target price for the stock from $180.00 to $310.00 in a research report on Thursday, August 6th. Twelve analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $255.65.
Read Our Latest Stock Analysis on Charles River Laboratories International
Charles River Laboratories International Profile
Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.
Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.
Featured Stories
- Five stocks we like better than Charles River Laboratories International
- Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
- Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
- NVIDIA’s $500 Billion GPU Financing Deal Fuels Path Toward $270
- Sandisk’s Margins Look Like Software. Can They Last?
Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL – Free Report).
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.
